Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Smith & Nephew Plc LSE:SN. London Ordinary Share GB0009223206 ORD USD0.20
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -9.00 -0.54% 1,660.50 1,670.50 1,672.00 1,680.00 1,637.50 1,646.50 2,650,973 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 3,874.2 560.2 51.7 29.5 14,525

Smith & Nephew Share Discussion Threads

Showing 776 to 800 of 900 messages
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
DateSubjectAuthorDiscuss
13/11/2017
12:15
Dodgy knees and hips aren't going away - keep buying.
its the oxman
03/11/2017
16:26
Looking for a safe home for some funds. Nice chart, reasonable valuation, defensive sector all looks nice. Update this morning states "Full year outlook at the lower end of guidance range" yet the shares are up over 2.0%. Can only assume the market is impressed by the CEO's buy which isn't particularly large for someone running a multi-billion pound company. Think I'll keep an eye on broker forecasts for now.
quant_investor
27/10/2017
10:20
SN. Smith @Nephew..reports on 3rd of November and im expecting share price to chase upwards to that date. Gap up at open on verge of 5 year breakout.
3rd eye
13/10/2017
12:58
S @ N Smith @ Nephew.............. https://www.bloomberg.com/news/articles/2017-10-10/singer-s-elliott-is-said-to-build-a-stake-in-smith-nephew
3rd eye
12/10/2017
12:58
inference was they have only got 0.5% but as you say nobody knows and it is definitely under 3% disclosable. if I was them, I would not be happy if they were building a stake.
edwardt
12/10/2017
08:01
Lot of discussion on FTs Alphaville yesterday.S&N figures coming up Nov 3rd,could be weak given hurricanes that have interrupted Florida hip replacement market.Doing various calculations,a target price of £17-80 is mentioned,this in the event of a bid I presume.Natter about breaking up Smith and Nephew.Johnson&Johnson and Stryker mentioned as perennial takeover possibles.Just what stake Eliott have taken remains unknown for now.
steeplejack
11/10/2017
13:58
perhaps sell it to vest his options before he goes - I know that is what I would be thinking :)
edwardt
11/10/2017
12:18
He's not going til the end of 2018 by which time he'll be in his 60th year.Happy retirement.
steeplejack
11/10/2017
11:11
stryker are the obvious home for it - not sure where they are at but recall they put in place a large buy back programme in 15 instead of bidding for sn. their balance sheet is very solid so they could easily make a juicy bid imo. lets see but funny how the ceo left abruptly....
edwardt
11/10/2017
10:10
Year's high.
steeplejack
11/10/2017
09:55
Elliott are renowned for shaking things up - the spat at BHP is illustrative of this.
edwardt
11/10/2017
09:14
Lets hope there might be something in it. Perennial bid candidate though - that's why I bought and hold. One day, Rodney.
broadwood
11/10/2017
09:11
FT reports this morning that the stock rose on news that Eliott Management had built a stake.Nothing more than that at the moment
steeplejack
11/10/2017
08:46
Elliot rumoured to have built a stake - can not see an rns to that effect - anyone know more?
edwardt
10/10/2017
21:07
Orderly?......Nasdaq up on big volume.Equivalent close on current xrates is £14-32
steeplejack
09/10/2017
09:18
CEO's retirement looks orderly. No need for a panic attack.
broadwood
04/10/2017
14:26
High volume today
samdb
10/9/2017
00:08
About time we had another bid story run riot in the press.
its the oxman
27/7/2017
11:02
Smith & Nephew (SN.), the medical equipment manufacturing company, reported revenue of $1,194m for the second quarter, which was flat on a reported basis and up 3% when foreign exchange headwinds and the gynaecology division disposal are excluded. The company saw a recovery in emerging markets, with revenue up 13% in the quarter. For the first half, the operating profit was $414m, up from $357m the previous year. The trading profit margin was 30 basis points higher at 21.1%, in line with guidance. The group said it continues to expect underlying revenue growth of 3-4% and a 20-70bps improvement in trading profit margin for the full year
broadwood
25/5/2017
10:06
New all time highs on an almost daily basis. And not a whisper in the press ...
mamcw
05/5/2017
09:35
Smith & Nephew said its full year outlook for underlying revenue growth remained unchanged in the 3%-4% range after posting flat first quarter revenue of $1.14bn, flat on a reported basis after -2% impact from the disposal of its gynaecology business and -1% currency headwind. Revenue was up 3% on an underlying basis for the period. Established markets, the US and other established markets revenue were all up 1%. "In Europe we are making progress improving our execution, although the slight headwinds seen last year in some European countries continued,"Smith & Nephew said. "Performance in the emerging markets was good, returning to double-digit growth, with China growing 14% in the quarter." "On a reported basis, we expect 2017 revenue growth to be in the range of 1.6%-2.6% based on prevailing exchange rates at the end of April and reflecting the 80bps headwind from the disposal of the gynaecology business," the company said.
broadwood
05/5/2017
07:26
Live bid candidate. - Smith & Nephew said its Q1 2017 trading was in line with its expectations, and that it was on track to deliver 3-4% underlying revenue growth for the FY. CEO Olivier Bohuon said that in particular the company's performance in the Emerging Markets was good, returning to double-digit growth, with China up 14% underlying. "Our innovative new products, such as the Lens camera and Werewolf Coblation systems, have been well received, and we look forward to the imminent full market release of the Total Knee Application on our Navio robotics-assisted surgery system," said Bohuon. "Over the last few years we have successfully put in place the right structures and capabilities to make the Group stronger, simpler, more agile and efficient. "We continue to focus on execution and expect to see progress through the year." Meantime, for Q1, revenue of $1.142bn was flat on a reported basis after -2% impact from Gynaecology disposal and -1% currency headwind. It was up 3% on an underlying basis. "Smith & Nephew is on-track to deliver 3-4% underlying revenue growth for full year," it said.
broadwood
10/3/2017
09:49
Now Akzo Nobel falls under the global consolidation hammer. Only a matter of time before SN is bought
mamcw
21/2/2017
15:42
Unilever situation underlines attractiveness of UK-based companies whose earnings are global to US predators.
mamcw
09/2/2017
18:58
Nice come back today. Forming a long lower wick to daily candle.
corlis
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
ADVFN Advertorial
Your Recent History
LSE
SN.
Smith & Ne..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200525 12:17:16